Aclaris Therapeutics (ACRS) PT Set at $50.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics (NASDAQ:ACRS) in a research note published on Monday. The brokerage currently has a buy rating on the biotechnology company’s stock.

ACRS has been the topic of a number of other research reports. Zacks Investment Research raised shares of Aclaris Therapeutics from a hold rating to a buy rating and set a $31.00 price target on the stock in a report on Tuesday, October 10th. BidaskClub raised shares of Aclaris Therapeutics from a sell rating to a hold rating in a report on Friday, December 29th. Finally, ValuEngine downgraded shares of Aclaris Therapeutics from a hold rating to a sell rating in a report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Aclaris Therapeutics presently has a consensus rating of Hold and a consensus target price of $39.20.

Shares of Aclaris Therapeutics (ACRS) traded up $0.09 during mid-day trading on Monday, reaching $25.51. 113,900 shares of the company traded hands, compared to its average volume of 292,900. Aclaris Therapeutics has a one year low of $21.32 and a one year high of $33.25. The stock has a market cap of $764.91 and a P/E ratio of -11.81.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.23. The company had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $2.00 million. analysts forecast that Aclaris Therapeutics will post -2.59 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its holdings in shares of Aclaris Therapeutics by 55.4% during the 2nd quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after acquiring an additional 697,104 shares during the last quarter. FMR LLC boosted its holdings in shares of Aclaris Therapeutics by 14.6% in the second quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock worth $51,425,000 after buying an additional 242,269 shares during the last quarter. Eagle Asset Management Inc. boosted its holdings in shares of Aclaris Therapeutics by 1.7% in the third quarter. Eagle Asset Management Inc. now owns 1,380,549 shares of the biotechnology company’s stock worth $36,446,000 after buying an additional 22,576 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Aclaris Therapeutics by 79.6% in the second quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock worth $33,880,000 after buying an additional 553,752 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Aclaris Therapeutics by 3.5% in the third quarter. Point72 Asset Management L.P. now owns 892,298 shares of the biotechnology company’s stock worth $23,030,000 after buying an additional 29,896 shares during the last quarter. 92.02% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Aclaris Therapeutics (ACRS) PT Set at $50.00 by Cantor Fitzgerald” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/12/aclaris-therapeutics-acrs-pt-set-at-50-00-by-cantor-fitzgerald.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply